JP2006169224A - Mrsa infection-alleviating dietary supplement - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide a method for alleviating MRSA infection and method for getting off from the infection by a dietary supplement including a transintestinal nutritious dietary supplement, and the dietary supplement and transintestinal nutritious dietary supplement aiming at the alleviation of the MRSA infection and departure from the infection. <P>SOLUTION: This method for alleviating the MRSA infection and method for getting off from the infection is provided by showing that the essence of Acanthopanax senticosus Harms contributes the alleviation of the infection of the MRSA-infected patients or the getting off from the infection, and further the dietary supplement and transintestinal nutritious dietary supplement aiming at the alleviation of the MRSA infection and getting off from the infection characterized by containing the essence of A. senticosus are also provided. <P>COPYRIGHT: (C)2006,JPO&NCIPI

Description

  The present invention relates to a supplement that improves the constitution of a methicillin-resistant Staphylococcus aureus (MRSA) -infected person and thereby reduces MRSA infection.

1. Methods for reducing MRSA infection or withdrawal from infection Various methods and inventions have already been provided in order to reduce MRSA infection or withdraw from infection. The most direct one is an antibiotic, and vancomycin is known as a specific medicine. The presence of vancomycin and teicoplanin in the presence of many antibiotics that are not effective against MRSA is strong, but they often do not exhibit sufficient antibacterial activity. The current situation is that treatment is performed in combination.

  MRSA is a resident bacterium, and just because it is infected does not mean that the carrier has developed an infection. Apparently healthy persons are often carriers, and therefore there is a limit to requesting medicines for measures against these healthy persons.

  In addition to pharmaceuticals, many materials with a bactericidal effect against MRSA are known. For example, for food materials, tea extract or its active fraction (when used in combination with β-lactam antibiotics) (see, for example, Patent Document 1), isoliquiritigenin or lycochalcone A in licorice (see, for example, Patent Document 2) , Fully-ripe garlic mushroom (for example, see Patent Document 3), tea leaves, mint leaves, dokudami leaf tea leaves (for example, see Patent Document 4), EGCg extracted from green tea, TF3 extracted from black tea (for example, see Non-Patent Document 1) , Catechins (see, for example, Non-Patent Document 2), and the like, have been reported to have an unprecedented number of materials, and means or methods for sterilizing MRSA have been invented. However, these inventions relate to the direct antibacterial action against MRSA, and even if the effect for the purpose of applying to or washing the infected part is expected, the mucous membrane part in the body can be washed directly. Or, the effect cannot be obtained for an infected site that is difficult to apply.

2. Nourishment tonic supplements It goes without saying that nutrients such as amino acids and vitamins have nourishing tonic effects, but there are food ingredients that show nourishing tonic effects through regulating body functions, not these direct nutrients. The fact that it has already been used for many years in the diet and partly in medicine is well known, not to mention the example of ginseng.

  Speaking of Ezokogi, which is a well-known food material that has nourishing and tonic effects, Ezocogi (Acanthopax senticosus Harm) is an anti-fatigue and immune stimulator in the Soviet Union, China, and Hokkaido in Japan. It has been used as a folk medicine for nourishing tonic and inflammatory diseases such as rheumatoid arthritis. In addition to eleuteroside E and eleuteroside B, chlorogenic acid and isofraxidine are listed as active ingredients in Ezoukogi extract. (For example, refer nonpatent literature 3).

  As a tonic effect, the anti-fatigue effect of the extract of Ezokogi water has been confirmed by a swimming test using rats. The main active substance is due to eleuteroside E, and the stress reducing action is also shown by the antiulcer action of rats. (For example, refer nonpatent literature 3 and 4).

  As another effect, isofluxidine leads to suppression of transcription of inflammatory cytokine genes and inflammatory protein genes in human synovial sarcoma cells SW982 cells that release inflammatory cytokines in rheumatoid arthritis. And suppression of the production of proteins that are the products of these genes (see, for example, Patent Document 5 and Non-Patent Document 5).

3. Tube Nutritional Food The present invention does not necessarily require tube feeding for the reduction of MRSA infection or withdrawal from infection. However, tube feeding has many aspects that overlap with the MRSA infection situation due to its application situation. That is, tube feeding is a nutrient intake method by artificially inserting a tube into the body, and such a surgical treatment is generally included in a treatment that easily causes infection. Furthermore, many people who take tube feeding are elderly people who have weakened physical strength or long-term care recipients, and are often poor in resistance to infection. In addition, many of those who take tube nutrition are so-called bedridden, and therefore often require ancillary treatments that tend to catch on with pressure ulcers and cause infections such as urination.

  Since the situation where MRSA infection is likely to occur overlaps with the situation of tube feeding intake, there is a great significance in providing MRSA infection mitigation or withdrawal methods or materials with tube feeding nutrition in mind. There is.

  For tube feeding, (1) classification by route, (2) classification by recipient, (3) classification by ingredient, (4) classification by drug or food, (5) classification by product form to be provided Etc., and products suitable for each purpose have been provided. The details are reviewed, for example, in Non-Patent Documents 6, 7, 8 and the like, but in summary, (1) the administration route includes the nasal method and the fistula method. Because fistulas are provided, sufficient care must be taken to prevent infection. (2) The recipients are inflammatory diseases, malabsorption syndromes, hypermetabolic diseases, ingestion is impossible, gastrointestinal rest is necessary, chronic hepatitis, kidney damage, preoperative, pre-test management, etc. . (3) Depending on the raw material components, there are ingredient nutrients, digestive nutrients, semi-digested nutrients, natural concentrated liquid foods and the like, and various prescriptions are provided according to the needs of the recipient. (4) Substances classified as pharmaceuticals include ingredient nutrients, digestive nutrients and semi-digestible nutrients, and those classified as foods include semi-digestible nutrients and natural concentrated liquid foods. . Further, (5) product forms include liquid forms such as cans, paper packs, and retorts, and powder forms or granular forms that are dissolved and administered.

Furthermore, supplementary nutrients for the purpose of supplementing vitamins, electrolytes, trace metal elements and the like are also provided for the purpose of improving enteral nutrition. However, as far as the inventors know, no supplemental nutrient has been provided for the purpose of reducing or eliminating MRSA infection.
Special table hei 9-509677 JP-A-7-2656 Japanese Patent No. 2711202 JP 2000-152771 A Japanese Patent Application No. 2003-374954 Toda Masako et al., Japanese Bacteriological Journal 46 (5): 839-844 (1991) Takehiko Takahashi et al., Journal of Infectious Diseases 69 (10): 1126-1133 (1995) Nishibe, S et al. (1990) Chem Pharm Bull, 38, 6, 1763-1765. Hidekatsu Takeda, (1990) Toho Medical Journal, 37, 3, 334-343 Taisuke Yamazaki et al. (2004), J. MoI. Electrophoresis, 48, 55. Tomoko Handa, Kenji Fujita. Types and features of enteral nutrients. medicina 35 (2) 339-341 (1998) Sadahito Sakurai. Recent advances in enteral nutrition. Japanese Surgical Society Journal 99 (3): 154-158 (1998) Sadahito Sakurai. Advances in enteral nutrition. Clinical and Research 76 (5): 972-976), (1999)

  It is an object of the present invention to provide a method for improving a patient's constitution and thus reducing methicillin-resistant Staphylococcus aureus (MRSA) infection, as well as a supplement suitable for that purpose. In particular, in the present invention, tube feeding supplements corresponding to this purpose are provided for tube feeding intakers who are easily infected with MRSA, and the content of the active ingredient is further included as such supplements. The guaranteed weevil extract is provided, but the present invention is not necessarily limited to tube feeding supplements, and is not limited to ezokogi as supplements. The use of known supplements of known nutritional tonicity for this purpose is included in the present invention.

Problems to be solved by the invention

  Drug-resistant bacteria, especially MRSA, are resistant to the majority of antibiotics, and their spread is a major threat in the medical field. MRSA is especially useful for hospitalized patients or caregivers who are susceptible to bacterial infection, such as respiratory infections, pressure ulcers, or tube feeding, when the elderly with weak physical strength and immunity are weakened. There is a high chance of infection and its removal is not easy. In addition, having such MRSA-infected persons places a great economic burden on the hospital, and thus a considerable burden on the Japanese medical economy.

  Conventionally, antibiotics and antibacterial substances have been used for the purpose of reducing or eliminating MRSA infection as outlined in the next section. However, in the present invention, a method for reducing MRSA infection indirectly is provided by changing this idea and providing supplementary foods known to enhance the physical strength and immunity of the patient or healer. I went to. That is, the problem to be solved by the present invention is to provide a novel method for reducing MRSA infection and a supplement suitable for the method without giving antibiotics or antibacterial agents.

Means for solving the problem

  As mentioned above, MRSA infection is a major threat in medical and nursing care settings. However, looking at the status of the infection, it is not always true that the infected person has been infected indefinitely, and it is often seen that the person withdraws from the infection. In particular, when MRSA infection is observed during treatment for various illnesses, it is often observed that MRSA infection can be withdrawn during recovery or rehabilitation without using antibiotics. It is done. The inventors focused on this fact and conducted extensive research. As a result, among supplements generally known to have nourishing tonic or immunostimulatory effects, there are those that help reduce MRSA infection or withdraw from infection. We found out that there was a present invention.

The invention's effect

  1. In addition to traditionally known antibiotics and antibacterials and applications, MRSA infection is demonstrated by administering nutritional tonic and immunostimulatory supplements to reduce MRSA infection or withdraw from infection. Provided a way to reduce infection or withdraw from infection.

  2. For the purpose of alleviating MRSA infection or aiming for withdrawal from infection, a supplementary food with nutritional tonic and immunostimulatory ability for tube feeding was provided.

  3. For the purpose of alleviating MRSA infection or aiming to withdraw from infection, a supplement containing Ezokogi extract was provided.

  4). In order to reduce MRSA infection or to escape from infection, an MRSA infection-reducing tube feeding supplement containing Ezokogi extract was provided.

  5. MRSA infection mitigation assistance containing Ezoukogi extract with daily doses of 100 μg or more for isofluxidine and 2.4 mg or more for eleuteroside E for the purpose of reducing MRSA infection or withdrawing from infection Provided food.

  6). In order to reduce MRSA infection or to escape from infection, MRSA infection mitigation process containing Ezoukogi extract whose daily dose is 100 μg or more for isofluxidine and 2.4 mg or more for eleuteroside E. Tube feeding supplements were provided.

BEST MODE FOR CARRYING OUT THE INVENTION

  In the following examples, an extract from a stem chip of domestically produced pearl millet is used as a nourishing tonic supplement, and this is used orally for MRSA-infected persons or as a supplement at the time of tube feeding. If it is used for the purpose of the present invention, the extract of the nutritional tonic supplement material that does not need to be domestically produced and does not need to be a stem and can be easily recalled by those skilled in the art can be used in the present invention. included.

Experimental Example 1 Preparation of Ekokogi Extract Ekokogi Extract was prepared by the following method in order to demonstrate the effect of the present invention. That is, 6 kg of sorghum stem (domestic) was extracted by heating with 100 L of boiling water. The filtrate was concentrated using a continuous vacuum concentrator and concentrated to around 5 L. The concentrate was sterilized by autoclaving (121 ° C., 20 minutes) after removing the residue by centrifugation and filter filtration.

The quantification of Ezokogi components was performed according to the following test method.
Isoflaxidine (IF): Health Supplement Standards Collection, Japan Health and Nutrition Food Association, Japan Chlorogenic acid (CA): Mitsutoshi Aoyagi, Quantification of Ezokogi components (4th report), Kohei Laboratories, 49th report, 137 ( 1990)
Eleutheroside B (EB) and Eleutheroside E (EE): USP / NF21,743
Arsenic: Japanese Pharmacopoeia B General Test Method Item 30 Arsenic Test Method (1)
Heavy Metals: Food Additives Official Test General Test Methods Heavy Metal Tests General Bacteria Count: Food Sanitation Inspection Guidelines Microorganisms (1990)
Coliform bacteria: Food Sanitation Inspection Guidelines Microorganism (1990)
In addition, the standard used was an isofraxidine standard product (manufactured by Wako Pure Chemical Industries, Ltd.), chlorogenic acid hemihydrate (manufactured by Wako Pure Chemical Industries, Ltd.), eleuteroside B and eleuteroside E (both Phytochem referrenzsubstanzen GbRmbH). .

Experimental Example 2 Administration Test An Ezocogi extract administration test was carried out for the healers who are being treated at Kita Shinagawa Hospital attached to Kono Clinical Medical Laboratory. The subjects are healers who are undergoing convalescent rehabilitation at this hospital, and elderly people with an average age of 77 years old and over 60 years old account for over 90%.

  There are a total of 37 recipients of Ezoukogi extract. The administration period is from April 26, 2004 to October 31. The administration product is Ezoukogi extract prepared as in Experimental Example 1, and the dosage is an amount corresponding to a hot water extract of 9 g of daily Ezokogi raw powder. The administration method was mixed with bancha or mixed with tube feeding (CZ-Hi).

  In addition, 8 persons who were MRSA positive before the administration out of 37 administered persons were set as the MRSA positive administration group. The choice of recipient and non-administrator was performed randomly. Among the non-administered patients, 17 MRSA-positive persons, and 45 patients including MRSA-positive persons who were MRSA-positive patients in 2003 who were not planned for this study, were 45 MRSA. Positive non-administration group. In order to avoid confusion in statistical calculations due to the dispersion of the period, the observation period exceeds 8 weeks for both the administration and non-administration groups from these two populations. Only those who had a week or longer and a treatment period of 4 weeks or longer were included. As a result of this selection, there were 6 recipients and 30 non-administered subjects.

  Prior to the administration study, the study plan should be reviewed by the Ethics Review Committee, and the consent of the person who received the administration, or the surrogate if it was impossible to obtain the consent of the subject prior to the study. Have participated in the exam.

  For MRSA positives, samples were taken weekly and subjected to MRSA testing. The MRSA test was performed in a five-step determination of negative, slight, 1+, 2+, and 3+ by a resistance test by the disc method against oxacillin (by Health Science Institute, Inc.). However, in this experiment, all the determinations other than negative were set to + as a numerical value 1, negative as 0, and evaluation based on only two stages of 1 and 0. Samples are primarily pharyngeal smears, but also include nasal passages, trachea, pressure ulcer secretions and urine. If the test is negative for 3 consecutive weeks, the test is completed.

  Table 2 shows the changes in MRSA for 4 weeks before administration and 4 weeks after administration.

  In Table 2, there was a tendency to reduce MRSA infection after administration. However, the subject is a healer who is undergoing rehabilitation treatment, and it cannot be denied that there is a tendency to reduce without administration. In addition, since the period during which the subject has undergone the MRSA test is dispersed in a long period from 4 weeks to over 30 weeks, it is undeniable that there may be a difference in the reduction tendency depending on the administration period or the observation period.

  Therefore, a comparison was made with non-administrators. For non-administrators, the entire observation period was n weeks, and when n was an even number, the observation period was divided into two at the n / 2 week and divided into the first half and the second half. When n is an odd number, the first half is n-1 / 2 weeks and the second half is n + 1/2 weeks. Thus, centering on the divided time point (intermediate point) obtained by dividing the observation period into two, the MRSA positive values for 4 weeks immediately before and 4 weeks immediately after that are the MRSA positive values in the non-administration period and the positive values in the administration period, respectively. A control value was used.

  In addition, for the administration group, there is an improvement when the average MRSA positive value before administration is reduced by 20% or more after administration, and for the non-administration group, there is an intermediate point in the observation period. The average MRSA positive value in the 4 weeks immediately before is reduced by 20% or more in the immediately following 4 weeks, and the number of improvers in the subject and the improvement rate are shown as being improved. 3.

  Based on this value, statistical calculation was performed by the parallel method of clinical comparative tests (non-administered group as control group) (Toshiyuki Furukawa, Toshiro Tango: Statistics on Medicine. Asakura Shoten 1983). If the Z value calculated by the parallel clinical trial calculation is 1.96 or more, the significance level is determined to be 5%. In this data, the Z value was 0.3236, which did not reach a significant level, but a high improvement trend was also seen in comparison with the non-administered group.

Claims (6)

Administration of supplements to reduce MRSA infection Tube feeding supplements to reduce MRSA infection MRSA infection reduction supplement containing Ezoukogi extract MRSA infection-reducing tube feeding supplement containing Ezoukogi extract MRSA infection-reducing supplement, characterized in that it is a supplement containing Ezoukogi extract, and the daily dose is 100 μg or more for the component isofluxidine and 2.4 mg or more for eleuteroside E MRSA infection-reducing tube characterized in that it is a dietary supplement containing Ezoukogi extract, and its daily dose is 100 μg or more for its component, isofluxidine, and 2.4 mg or more for eleuteroside E Dietary supplement